STABL — Stayble Therapeutics AB Share News
0.000.00%
Last trade - 00:00- SEK14.03m
- SEK12.43m
Brief: Stayble Therapeutics Engages Ferghana To Support Partnering Activities
Brief: Stayble Therapeutics Ends Liquidity Guarantee Agreement With Lago Kapital
Brief: Stayble Therapeutics Q2 EBIT Loss Widens To SEK 6.9 Mln
Brief: Stayble Therapeutics Q1 EBIT Loss Narrows To SEK 3.8 Mln
Brief: Stayble Therapeutics Raises About SEK 31.7 Mln Through Rights Issue
Brief: Stayble Therapeutics Gets Subscription Commitments, Top Guarantee In Rights Issue From Major Shareholders
Brief: Stayble Therapeutics Gets Approval To Start Phase 1b Study
Brief: Stayble Therapeutics Resolves On Rights Issue Of About SEK 35.2 Mln
Brief: Stayble Therapeutics Q4 EBIT Loss At SEK 4.6 Mln
Brief: Stayble Therapeutics Q3 EBIT Loss SEK 6.1 Million
Brief: Stayble Therapeutics Q2 EBIT Loss Widens To SEK 6.6 Million
Brief: Stayble Therapeutics Q1 EBIT Loss Widens To SEK 7.5 Mln
Brief: Stayble Therapeutics Q4 EBIT Loss Widens To SEK 4.6 Million
Brief: Stayble Q3 Net Loss Widens To SEK 3.0 Mln
Brief: Stayble Therapeutics Q1 EBIT Loss Narrows To SEK 2.1 Million
Brief: Stayble Therapeutics To Report STA363 Study Results During H2 2022
Brief: Stayble Therapeutics Q4 EBIT Loss Narrows To SEK 0.9 Mln
Brief: Stayble Therapeutics Rights Issue Oversubscibed
Brief: Stayble Therapeutics Raises About SEK 88,000 Through Exercise Of Warrants